

Bibliographie – Equipe V. Vieillard (2019-2021)

2021

Avettand-Fenoel V, Lechenadec J, Diallo MS, Fillion M, Melard A, **Samri A**, Dollfus C, Blanche S, Faye A, Amokrane K, **Autran B**, Buseyne F, Warszawski J, Frange P; ANRS-EP59-CLEAC Study Group. Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence. *Clin Infect Dis*. 2021 Dec 6;73(11):e4214-e4222.

Bailly B, Péré H, Veyer D, Berceanu A, Daguindau E, Roux P, Hermine O, de Lamballerie X, Bastard P, Lacombe K, **Autran B**, Angelot Delettre F, Casanova JL, Imbeaud S, Clairet AL, Kroemer M, Spehner L, Robillard N, Puech J, Marty-Quinnet S, Lepiller Q, Chirouze C, Bouiller K. Persistent COVID-19 in an immunocompromised host treated by SARS-CoV-2-specific monoclonal antibodies. *Clin Infect Dis*. 2021 Oct 1:ciab868.

Klingler J, Paul N, Laumond G, Schmidt S, Mayr LM, Decoville T, Lambotte O, **Autran B**, Bahram S, Moog C; and for ANRS CO21 Cohort. Distinct antibody profiles in HLA-B*57+, HLA-B*57- HIV controllers and chronic progressors. *AIDS*. 2021 Sep 27.

Maucourant C, Nonato Queiroz GA, Corneau A, Leandro Gois L, Meghraoui-Kheddar A, **Tarantino N**, Bandeira AC, **Samri A**, Blanc C, Yssel H, Rios Grassi MF, **Vieillard V**. NK Cell Responses in Zika Virus Infection Are Biased towards Cytokine-Mediated Effector Functions. *J Immunol*. 2021 Sep 1;207(5):1333-1343.

Tarantino N, Leboyer M, Bouleau A, Hamdani N, Richard JR, Boukouaci W, Ching-Lien W, Godin O, Bengoufa D, Le Corvoisier P, Barau C, Ledudal K, **Debré P**, Tamouza R, **Vieillard V**. Natural killer cells in first-episode psychosis: an innate immune signature? *Mol Psychiatry*. 2021 Sep;26(9):5297-5306.

Nakid-Cordero C, **Choquet S**, Gauthier N, Balegroune N, **Tarantino N**, **Morel V**, Arzouk N, Burrel S, Rousseau G, Charlotte F, Larsen M, **Vieillard V**, **Autran B**, **Leblond V**, **Guihot A**; K-VIROGREF Study Group. Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. *Am J Transplant*. 2021 Aug;21(8):2846-2863.

Bouzidi A, Labreche K, **Baron M**, Veyri M, Denis JA, Touat M, Sanson M, Davi F, Guillerm E, Jouannet S, Charlotte F, Bielle F, **Choquet S**, Boëlle PY, Cadranet J, **Leblond V**, **Autran B**, Lacorte JM, Spano JP, Coulet F; IDEATION study group. Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations. *Front Cell Dev Biol*. 2021 Aug 3;9:661272.

Hervier B, Ribon M, **Tarantino N**, Mussard J, Breckler M, **Vieillard V**, Amoura Z, Steinle A, Klein R, Kötter I, Decker P. Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus. *Front Immunol*. 2021 May 3;12:633658.

Blumental S, **Debré P**. Challenges and Issues of Anti-SARS-CoV-2 Vaccines. *Front Med (Lausanne)*. 2021 May 14;8:664179.

Samri A, Chalouni M, Blanco J, Behrens G, Kelleher P, Massanella M, Ahmad F, Clotet B, Plettenberg A, Katlama C, Richert L, Raffi F, Thiebaut R, **Autran B**; NEAT 001/ANRS 143 Trial Study Group. Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in Naïve HIV-1-Infected Patients. *J Acquir Immune Defic Syndr*. 2021 Apr 15;86(5):e146-e149.

Nakid-Cordero C, **Baron M**, **Guihot A**, **Vieillard V**. Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders. *Cancers (Basel)*. 2021 Apr 12;13(8):1836.

Fontanet A, **Autran B**, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. *Lancet*. 2021 Mar 13;397(10278):952-954.

Diallo MS, **Samri A**, Charpentier C, Bertine M, Cheynier R, Thiébaud R, Matheron S, Collin F, Braibant M, Candotti D, Brun-Vézinet F, **Autran B**; ANRS CO5 IMMUNOVIR-2 and ANRS CO15 ALT Study Groups. A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. *AIDS Res Hum Retroviruses*. 2021 Mar;37(3):214-223.

Karoyan P, **Vieillard V**, Gómez-Morales L, Odile E, **Guihot A**, Luyt CE, Denis A, Grondin P, Lequin O. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. *Commun Biol*. 2021 Feb 12;4(1):197.